These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38190588)

  • 1. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
    Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
    JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
    J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
    Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
    Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
    Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
    Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
    Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone-modifying Agents (BMAs) in Breast Cancer.
    Shapiro CL
    Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
    Sheedy KC; Camara MI; Camacho PM
    Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
    Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
    Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
    Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
    Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
    J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
    Miller K; Steger GG; Niepel D; Lüftner D
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.